Latest Geovax Labs Inc (GOVX) Headlines GeoVa
Post# of 109
Posted On: 03/10/2014 1:04:13 AM
Latest Geovax Labs Inc (GOVX) Headlines
GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Mar 05, 7:15AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update.
GeoVax Presents at the Phacilitate Vaccine Forum 2014
Marketwire - Tue Jan 28, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.
GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
Marketwire - Thu Jan 23, 9:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today the publication of the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11. The article, titled "Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles" was published on-line in The Journal of Infectious Diseases. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24403557.
GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients
Marketwire - Mon Jan 13, 7:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today preliminary top-line results from GV-TH-01, a Phase 1 clinical trial investigating the ability of the Company's GOVX-B11 vaccine to control HIV infections in patients who initiated antiretroviral drug treatment within 18 months of seroconversion. The Company expects to release additional results from this trial as final analyses are completed, and in conjunction with scientific presentations and publications.
Immunomedics (IMMU) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:25AM CST
Immunomedics was a big mover last session, with shares rising over 10%.
Best's Rating Notification - Cincinnati Specialty Underwriters Ins Co
Rating Division - AMBest - Thu Dec 19, 1:31PM CST
A.M. Best Company has made the following rating update:
Athersys (ATHX) in Focus: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 7:32AM CST
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
GeoVax Announces $1.65M Private Placement
Marketwire - Thu Dec 12, 7:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series B convertible preferred stock at an aggregate purchase price of $1.65 million. No stock purchase warrants were issued in conjunction with the transaction.
MiMedx Group (MDXG) in Focus: Stock Moves Up 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 02, 6:57AM CST
MiMedx Group, Inc. (MDXG) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
GeoVax Labs Inc names Dr Arban Domi as director of Vector Development
M2 - Mon Nov 25, 3:34AM CST
Biotechnology company GeoVax Labs Inc (OTCQB:GOVX) announced on Friday the addition of Dr Arban Domi, PhD as director of its Vector Development.
GeoVax Appoints Dr. Arban Domi as Director, Vector Development
Marketwire - Fri Nov 22, 8:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today announced the appointment of Arban Domi, Ph.D., as its Director, Vector Development.
GeoVax Chief Scientific Officer Lectures at the Texas A&M Health Science Center College of Medicine
Marketwire - Mon Nov 18, 2:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today announced that Chief Scientific Officer, Harriet L. Robinson, Ph.D., presented the 20th Annual Jesse D. Ibarra, Jr., MD Lectureship in International Health at Scott and White Healthcare and the Texas A&M Health Science Center (TAMHSC) College of Medicine. The presentation was on Friday, November 15, as part of TAMHSC Grand Rounds lecture series.
GeoVax Reports 2013 Third Quarter Financial Results
Marketwire - Tue Nov 12, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today reported financial results and recent developments for the three and nine months ended September 30, 2013.
GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV
Marketwire - Wed Oct 09, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today presented additional results from HVTN 205, a multicenter, randomized Phase 2a trial evaluating the safety and immunogenicity of the Company's first generation preventive HIV vaccine, at the 2013 AIDS Vaccine Meeting in Barcelona, Spain. At 6 months post-vaccination, patient antibody levels had declined less than 3-fold, indicating significant durability of the antibody response.
GeoVax Labs Inc awarded Notice of Patent Allowance in the US for DNA/MVA HIV vaccine technology
M2 - Tue Oct 08, 10:18AM CDT
Biotechnology company GeoVax Labs Inc (OTCQB:GOVX) reported on Monday the receipt of a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 10/336,566 entitled "Compositions and Methods for Generating an Immune Response."
GeoVax Receives Notice of Patent Allowance for DNA/MVA Vaccine for HIV/AIDS
Marketwire - Mon Oct 07, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing preventive and therapeutic HIV vaccines, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 10/336,566 entitled, "Compositions and Methods for Generating an Immune Response." The patent, exclusively licensed from Emory University and the U.S. Government, broadly covers compositions, methods, and uses of the GeoVax's DNA/MVA vaccine in eliciting cellular and humoral immune responses to an HIV antigen.
OTC Signal Daily Stock Watch - GeoVax Labs, Inc.. (OTCQB: GOVX)
WorldStockWire - Mon Sep 09, 1:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
HIV-1 Infection - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs2x4k/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2013" report to their offering. 'HIV-1 Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. Scope - A snapshot of the global therapeutic scenario for HIV-1 Infection. - A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the HIV-1 Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. United Biomedical, Inc. Aphios Corporation Pfizer Inc. Koronis Pharmaceuticals, Inc. Crucell N.V. GeoVax Labs, Inc. Enzo Biochem, Inc. ConjuChem Biotechnologies Inc. Critical Outcome Technologies Inc. Takara Bio Inc. Functional Genetics, Inc. Nutri Pharma ASA Quantum Pharmaceuticals Italfarmaco S.p.A. Statens Serum Institut and much more... For more information visit http://www.researchandmarkets.com/research/fs..._infection About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GeoVax Reports Financial Results for the Second Quarter and First Half 2013 and Provides Clinical Development Update
Marketwire - Mon Aug 12, 4:06PM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the six months ended June 30, 2013 and provided a clinical development update.
GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
Marketwire - Wed Mar 05, 7:15AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update.
GeoVax Presents at the Phacilitate Vaccine Forum 2014
Marketwire - Tue Jan 28, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on January 27, 2014 in Washington, DC.
GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases
Marketwire - Thu Jan 23, 9:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today the publication of the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11. The article, titled "Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles" was published on-line in The Journal of Infectious Diseases. An abstract of the article can be located at http://www.ncbi.nlm.nih.gov/pubmed/24403557.
GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients
Marketwire - Mon Jan 13, 7:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX) announced today preliminary top-line results from GV-TH-01, a Phase 1 clinical trial investigating the ability of the Company's GOVX-B11 vaccine to control HIV infections in patients who initiated antiretroviral drug treatment within 18 months of seroconversion. The Company expects to release additional results from this trial as final analyses are completed, and in conjunction with scientific presentations and publications.
Immunomedics (IMMU) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:25AM CST
Immunomedics was a big mover last session, with shares rising over 10%.
Best's Rating Notification - Cincinnati Specialty Underwriters Ins Co
Rating Division - AMBest - Thu Dec 19, 1:31PM CST
A.M. Best Company has made the following rating update:
Athersys (ATHX) in Focus: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 7:32AM CST
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
GeoVax Announces $1.65M Private Placement
Marketwire - Thu Dec 12, 7:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series B convertible preferred stock at an aggregate purchase price of $1.65 million. No stock purchase warrants were issued in conjunction with the transaction.
MiMedx Group (MDXG) in Focus: Stock Moves Up 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 02, 6:57AM CST
MiMedx Group, Inc. (MDXG) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
GeoVax Labs Inc names Dr Arban Domi as director of Vector Development
M2 - Mon Nov 25, 3:34AM CST
Biotechnology company GeoVax Labs Inc (OTCQB:GOVX) announced on Friday the addition of Dr Arban Domi, PhD as director of its Vector Development.
GeoVax Appoints Dr. Arban Domi as Director, Vector Development
Marketwire - Fri Nov 22, 8:00AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today announced the appointment of Arban Domi, Ph.D., as its Director, Vector Development.
GeoVax Chief Scientific Officer Lectures at the Texas A&M Health Science Center College of Medicine
Marketwire - Mon Nov 18, 2:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today announced that Chief Scientific Officer, Harriet L. Robinson, Ph.D., presented the 20th Annual Jesse D. Ibarra, Jr., MD Lectureship in International Health at Scott and White Healthcare and the Texas A&M Health Science Center (TAMHSC) College of Medicine. The presentation was on Friday, November 15, as part of TAMHSC Grand Rounds lecture series.
GeoVax Reports 2013 Third Quarter Financial Results
Marketwire - Tue Nov 12, 12:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today reported financial results and recent developments for the three and nine months ended September 30, 2013.
GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV
Marketwire - Wed Oct 09, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today presented additional results from HVTN 205, a multicenter, randomized Phase 2a trial evaluating the safety and immunogenicity of the Company's first generation preventive HIV vaccine, at the 2013 AIDS Vaccine Meeting in Barcelona, Spain. At 6 months post-vaccination, patient antibody levels had declined less than 3-fold, indicating significant durability of the antibody response.
GeoVax Labs Inc awarded Notice of Patent Allowance in the US for DNA/MVA HIV vaccine technology
M2 - Tue Oct 08, 10:18AM CDT
Biotechnology company GeoVax Labs Inc (OTCQB:GOVX) reported on Monday the receipt of a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 10/336,566 entitled "Compositions and Methods for Generating an Immune Response."
GeoVax Receives Notice of Patent Allowance for DNA/MVA Vaccine for HIV/AIDS
Marketwire - Mon Oct 07, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing preventive and therapeutic HIV vaccines, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 10/336,566 entitled, "Compositions and Methods for Generating an Immune Response." The patent, exclusively licensed from Emory University and the U.S. Government, broadly covers compositions, methods, and uses of the GeoVax's DNA/MVA vaccine in eliciting cellular and humoral immune responses to an HIV antigen.
OTC Signal Daily Stock Watch - GeoVax Labs, Inc.. (OTCQB: GOVX)
WorldStockWire - Mon Sep 09, 1:30AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
HIV-1 Infection - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs2x4k/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H2 2013" report to their offering. 'HIV-1 Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for HIV-1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-1 Infection. Scope - A snapshot of the global therapeutic scenario for HIV-1 Infection. - A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the HIV-1 Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. United Biomedical, Inc. Aphios Corporation Pfizer Inc. Koronis Pharmaceuticals, Inc. Crucell N.V. GeoVax Labs, Inc. Enzo Biochem, Inc. ConjuChem Biotechnologies Inc. Critical Outcome Technologies Inc. Takara Bio Inc. Functional Genetics, Inc. Nutri Pharma ASA Quantum Pharmaceuticals Italfarmaco S.p.A. Statens Serum Institut and much more... For more information visit http://www.researchandmarkets.com/research/fs..._infection About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GeoVax Reports Financial Results for the Second Quarter and First Half 2013 and Provides Clinical Development Update
Marketwire - Mon Aug 12, 4:06PM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the six months ended June 30, 2013 and provided a clinical development update.
(0)
(0)GeoVax Labs, Inc. (GOVX) Stock Research Links
Scroll down for more posts ▼